Koya Medical, a healthcare company with a mission to transform venous and lymphatic treatments through novel, people-centric solutions, announced that the full results from the TEAYS (Treatment Effectiveness of a Non-Pneumatic Compression Device versus an Advanced Pneumatic Compression Device for Lower Extremity Lymphedema Swelling) clinical study were published in the Journal of Vascular Surgery (JVS). According to the company, the data highlight superior efficacy and improved quality of life for patients suffering from lower extremity lymphedema with Koya Medical’s Dayspring, a novel non-pneumatic compression device (NPCD), compared to advanced pneumatic compression devices (APCDs). Further Reading: FDA Clears Dayspring Lite Lymphedema Treatment from Koya Medical
**Dayspring:**
* **Primary Outcome:** Reduced swelling in the affected limb.
Key Findings from the TEAYS Study: Efficacy: Patients using Dayspring experienced a mean limb volume reduction of 369.9 mL, significantly greater than the 83.1 mL reduction observed in the APCD treatment arm. Patients using Dayspring experienced a mean limb volume reduction of 369.9 mL, significantly greater than the 83.1 mL reduction observed in the APCD treatment arm. Quality of Life: Significant improvements were noted in the overall Lymphedema Quality of Life Questionnaire (LYMQOL) scores for Dayspring users, with a mean improvement of 1.01 compared to 0.17 for APCD users. Key functional sub-scores such as symptoms, appearance, and function also favored Dayspring.
The study also highlighted the importance of patient-centered care in managing lymphedema. Patient-centered care involves tailoring treatment plans to individual needs and preferences, and it is crucial for improving patient outcomes. Furthermore, the study found that Dayspring users experienced a significant reduction in pain and discomfort associated with lymphedema.
Lymphedema is a complex condition with a variety of causes, including:
* **Damage to the lymphatic system:** This can occur due to surgery, radiation therapy, or infection. * **Genetic predisposition:** Some individuals are genetically predisposed to developing lymphedema. * **Cancer treatments:** Certain cancer treatments, such as lymph node removal, can lead to lymphedema.
Dayspring is indicated to treat lymphedema, primary lymphedema, post-mastectomy edema, edema following trauma and sports injuries, post immobilization edema, venous insufficiency, venous stasis ulcers, or arterial and diabetic leg ulcers, lipedema and phlebolymphedema and other similar conditions that impact lymphatic flow in the upper and lower extremities. Dayspring is also indicated to reduce wound healing time and treatment and assist in healing stasis dermatitis. About Koya Medical Koya Medical is a healthcare company developing treatments for lymphedema and venous diseases to increase movement, mobility, and personalized care that is unavailable with traditional compression therapy. The privately held company was founded in 2018 with the mission to transform lymphatic and vein care through innovative patient-centric platforms.
Featured image: The Dayspring compression system, available for upper and lower extremity lcare, is a non-pneumatic treatment that integrates compression, muscle pump activation, and mobility in one easy-to-use solution for lymphedema. Photo: Koya Medical